Insider trade

CEO sold ~$435K of TWST shares in the open market

Traded Sep 24, 2026 · Filed Sep 26, 2026

Why it stands out

The CEO of Twist Bioscience sold $435K of Twist Bioscience shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

CEO$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$435,450

Shares × reported transaction price

Timing vs results

52 days after results of Aug 3, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 15, 2026.
Represents the weighted average sales price per share. The shares sold at prices ranging from $175 to $175.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Automatic saleFiled yesterday

Automatic saleFiled yesterday

Automatic saleFiled yesterday